English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Highlights From the 30th Congress of ISTH
Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B
Presented by: Guy Young, MD, Keck School of Medicine of USC, Los Angeles, California, United States
G. Young1, P. Chowdary2, S. Barton3, D. Yee3, F. Ferrante3
1Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA, Los Angeles, California, United States
2Royal Free Hospital, London, England, United Kingdom
3Freeline, Stevenage, England, United Kingdom
Key Data Points
FIX levels for the first 3 patients with hemophilia B dosed with FLT180a AAV gene therapy in the phase 1/2 B-LIEVE study. FIX values are from a one-stage assay at a central laboratory; horizontal dashed line is the lower limit of normal FIX expression (50 IU/dL). As of the May 23, 2022, data cut, FIX levels were 93, 92, and 80 at study day 77, 56, and 36 for patients 1, 2, and 3, respectively.
FIX (red) and ALT (yellow) levels for the 3 patients dosed with FLT180a in the B-LIEVE study. Three weeks after FLT180a infusion, patients began a tapering course of oral corticosteroids and a short course of oral tacrolimus as prophylaxis to minimize vector-related immune responses. Vertical dotted lines are prophylactic exogenous FIX infusions received on days after FLT180a infusion.
RELATED CONTENT
